CD19 and neoplasm: Labelling and gating strategies were developed to quantify tumour infiltrating lymphocytes (TILs) (CD3/CD4/CD8/CD19) and myeloid lineage cells (CD45+/CD11b+; macrophages: CD11b+/Ly6GlowF4/80+; neutrophils: CD11b+/Ly6Ghi; and dendritic cells CD11b+/CD11c+).